| Clinical relevance of the ESKAPE pathogens JN Pendleton, SP Gorman, BF Gilmore Expert review of anti-infective therapy 11 (3), 297-308, 2013 | 1565 | 2013 |
| Alternatives to antibiotics—a pipeline portfolio review L Czaplewski, R Bax, M Clokie, M Dawson, H Fairhead, VA Fischetti, ... The Lancet infectious diseases 16 (2), 239-251, 2016 | 901 | 2016 |
| Microbiological interactions with cold plasma P Bourke, D Ziuzina, L Han, PJ Cullen, BF Gilmore Journal of applied microbiology 123 (2), 308-324, 2017 | 354 | 2017 |
| Staphylococcus epidermidis device‐related infections: pathogenesis and clinical management MT McCann, BF Gilmore, SP Gorman Journal of Pharmacy and Pharmacology 60 (12), 1551-1571, 2008 | 330 | 2008 |
| Antibiofilm activities of 1-alkyl-3-methylimidazolium chloride ionic liquids L Carson, PKW Chau, MJ Earle, MA Gilea, BF Gilmore, SP Gorman, ... Green Chemistry 11 (4), 492-497, 2009 | 320 | 2009 |
| Application of ω-Transaminases in the Pharmaceutical Industry SA Kelly, S Pohle, S Wharry, S Mix, CCR Allen, TS Moody, BF Gilmore Chemical reviews 118 (1), 349-367, 2018 | 307 | 2018 |
| Hugo and Russell's pharmaceutical microbiology BF Gilmore, SP Denyer John Wiley & Sons, 2023 | 285 | 2023 |
| Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro EM Ryan, MY Alkawareek, RF Donnelly, BF Gilmore FEMS Immunology & Medical Microbiology 65 (2), 395-398, 2012 | 244 | 2012 |
| Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy EM Ryan, SP Gorman, RF Donnelly, BF Gilmore Journal of Pharmacy and Pharmacology 63 (10), 1253-1264, 2011 | 235 | 2011 |
| Eradication of Pseudomonas aeruginosa Biofilms by Atmospheric Pressure Non-Thermal Plasma MY Alkawareek, QT Algwari, G Laverty, SP Gorman, WG Graham, ... Public Library of Science 7 (8), e44289, 2012 | 234 | 2012 |
| The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli L Carson, SP Gorman, BF Gilmore FEMS Immunology & Medical Microbiology 59 (3), 447-455, 2010 | 234 | 2010 |
| The potential of antimicrobial peptides as biocides G Laverty, SP Gorman, BF Gilmore International journal of molecular sciences 12 (10), 6566-6596, 2011 | 212 | 2011 |
| Potential cellular targets and antibacterial efficacy of atmospheric pressure non-thermal plasma MY Alkawareek, SP Gorman, WG Graham, BF Gilmore International journal of antimicrobial agents 43 (2), 154-160, 2014 | 207 | 2014 |
| The antimicrobial potential of ionic liquids: A source of chemical diversity for infection and biofilm control JN Pendleton, BF Gilmore International journal of antimicrobial agents 46 (2), 131-139, 2015 | 191 | 2015 |
| Antimicrobial and antibiofilm activities of 1-alkylquinolinium bromide ionic liquids A Busetti, DE Crawford, MJ Earle, MA Gilea, BF Gilmore, SP Gorman, ... Green Chemistry 12 (3), 420-425, 2010 | 190 | 2010 |
| Biomolecular Mechanisms of Pseudomonas aeruginosa and Escherichia coli Biofilm Formation G Laverty, SP Gorman, BF Gilmore Pathogens 3 (3), 596-632, 2014 | 185 | 2014 |
| Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection SM Abdelghany, DJ Quinn, RJ Ingram, BF Gilmore, RF Donnelly, ... International journal of nanomedicine, 4053-4063, 2012 | 184 | 2012 |
| Cold plasmas for biofilm control: opportunities and challenges BF Gilmore, PB Flynn, S O’Brien, N Hickok, T Freeman, P Bourke Trends in biotechnology 36 (6), 627-638, 2018 | 160 | 2018 |
| Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with … J Deacon, SM Abdelghany, DJ Quinn, D Schmid, J Megaw, RF Donnelly, ... Journal of Controlled Release 198, 55-61, 2015 | 154 | 2015 |
| Antimicrobial activity of short, synthetic cationic lipopeptides G Laverty, M McLaughlin, C Shaw, SP Gorman, BF Gilmore Chemical biology & drug design 75 (6), 563-569, 2010 | 137 | 2010 |
